TY - JOUR
T1 - Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data
AU - Betancourt, Lazaro Hiram
AU - Pawłowski, Krzysztof
AU - Eriksson, Jonatan
AU - Szasz, A. Marcell
AU - Mitra, Shamik
AU - Pla, Indira
AU - Welinder, Charlotte
AU - Ekedahl, Henrik
AU - Broberg, Per
AU - Appelqvist, Roger
AU - Yakovleva, Maria
AU - Sugihara, Yutaka
AU - Miharada, Kenichi
AU - Ingvar, Christian
AU - Lundgren, Lotta
AU - Baldetorp, Bo
AU - Olsson, Håkan
AU - Rezeli, Melinda
AU - Wieslander, Elisabet
AU - Horvatovich, Peter
AU - Malm, Johan
AU - Jönsson, Göran
AU - Marko-Varga, György
N1 - Funding Information:
This study was supported by the Mrs Berta Kamprad Foundation, ThermoFisher Scientific, and Liconic with Biobank technology, and was also supported by grants from the National Research Foundation of Korea, funded by the Korean government (2015K1A1A2028365 and 2016K2A9A1A03904900) and Brain Korea 21 Plus Project, Republic of Korea, as well as the NIH/NCI International Cancer Proteogenome Consortium (MOU NIH LUND 2017-01), and the European Cancer Moonshot Lund Center scientific and outreach activities, through which data will be made public. G.J. was supported by the Swedish Cancer Society and the Swedish Research Council. A.M.S. was supported by the KNN121510 and NVKP_16-1-2016-0042 grants by the National Research, Development and Innovation Office of Hungary and Bolyai Research Scholarship of the Hungarian Academy of Sciences.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Metastatic melanoma is one of the most common deadly cancers, and robust biomarkers are still needed, e.g. to predict survival and treatment efficiency. Here, protein expression analysis of one hundred eleven melanoma lymph node metastases using high resolution mass spectrometry is coupled with in-depth histopathology analysis, clinical data and genomics profiles. This broad view of protein expression allowed to identify novel candidate protein markers that improved prediction of survival in melanoma patients. Some of the prognostic proteins have not been reported in the context of melanoma before, and few of them exhibit unexpected relationship to survival, which likely reflects the limitations of current knowledge on melanoma and shows the potential of proteomics in clinical cancer research.
AB - Metastatic melanoma is one of the most common deadly cancers, and robust biomarkers are still needed, e.g. to predict survival and treatment efficiency. Here, protein expression analysis of one hundred eleven melanoma lymph node metastases using high resolution mass spectrometry is coupled with in-depth histopathology analysis, clinical data and genomics profiles. This broad view of protein expression allowed to identify novel candidate protein markers that improved prediction of survival in melanoma patients. Some of the prognostic proteins have not been reported in the context of melanoma before, and few of them exhibit unexpected relationship to survival, which likely reflects the limitations of current knowledge on melanoma and shows the potential of proteomics in clinical cancer research.
UR - http://www.scopus.com/inward/record.url?scp=85063494011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063494011&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-41625-z
DO - 10.1038/s41598-019-41625-z
M3 - Article
C2 - 30914758
AN - SCOPUS:85063494011
SN - 2045-2322
VL - 9
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 5154
ER -